Europe’s Wegovy market is expected to grow at a CAGR of 16.3% between 2024 and 2030, supported by increasing awareness of obesity-related health risks and wider GLP-1 drug acceptance. Governmental health initiatives and the rise in sedentary lifestyles are major market drivers. However, varying regulatory pathways and healthcare reimbursement systems across countries restrain harmonized growth. Trends include a growing inclination toward pharmacological obesity treatments and physician-led digital obesity clinics. Opportunities are present in cross-border collaborations and harmonizing reimbursement policies to improve access across both Western and Eastern Europe.
TABLE - Europe Source: Company Publications, Primary Interviews, and SR Analysis
Europe 2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
CAGR (2024-2033)
U.K.
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
Germany
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
France
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
Total
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
TABLE - Europe Wegovy Market Size & Forecast By Route of Administration 2021-2033
Route of Administration | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Injectable (Subcutaneous) | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Oral (Pipeline) | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - Europe Wegovy Market Size & Forecast By End-User 2021-2033
End-User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospitals & Clinics | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Retail Pharmacies | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Online/Telehealth Platforms | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis